We are concerned that the European Parliament’s position moves away from the original objective of creating a simpler, more proportionate framework for genetically modified microorganisms innovation in Europe.
The amendments risk adding new restrictions, duplicating existing safety assessments and making the regulatory pathway more complex, without delivering demonstrable additional safety benefits.This matters because the EU is already falling behind: innovative solutions are reaching farmers in other parts of the world, while they remain unavailable to farmers in the EU.
The next stage of negotiations should focus on removing unnecessary duplication and at least ensuring requirements are proportionate, while maintaining Europe’s high safety standards and supporting investment in innovation in Europe